Daiwa Securities Group Inc. Arbutus Biopharma Corp Call Options Transaction History
Daiwa Securities Group Inc.
- $21.6 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ABUS
# of Institutions
156Shares Held
99.5MCall Options Held
2.31MPut Options Held
525K-
Morgan Stanley New York, NY21.7MShares$78.8 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY12.9MShares$46.7 Million26.34% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$41.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.92MShares$32.4 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY8.39MShares$30.4 Million10.86% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $544M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...